Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMEA Will Evaluate All NSAIDs In Search Of Potential “Class Effect”

This article was originally published in The Tan Sheet

Executive Summary

The EU health authority will undertake its own review of all non-steroidal anti-inflammatory drugs in light of safety concerns surrounding COX-2 inhibitors

You may also be interested in...



EMEA Calls For NSAID Labeling Consistency, Notes “No New Safety Concerns”

Labeling regarding established NSAID safety concerns should be made consistent across European Union member states, the European Medicines Agency said Oct. 17

EMEA Calls For NSAID Labeling Consistency, Notes “No New Safety Concerns”

Labeling regarding established NSAID safety concerns should be made consistent across European Union member states, the European Medicines Agency said Oct. 17

EMEA Calls For NSAID Labeling Consistency, Notes “No New Safety Concerns”

Labeling regarding established NSAID safety concerns should be made consistent across European Union member states, the European Medicines Agency said Oct. 17

Related Content

Topics

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel